Since initially recommending it at $72.40 on Oct. 23, we’re now up about $100 a share, as it pushes to $172 in pre-market. It could move higher as it nears its meeting with the US FDA on Dec. 17 with regards to emergency use authorization.
We also recommended BioNTech (BNTX) at $93.60. It’s now up to $130 a share, as it also nears emergency use authorization with the US FDA, too.
In addition, after recommending Pfizer (PFE) at $38.38 and watching it explode to $43, we’re reiterating a buy on this morning. We’d like to see the stock closer to $50 a share if the US FDA grants emergency use.
Congratulations on these vaccine wins.
We’d love to hear how you’re doing with these when you have a chance.